Check this one pout Van -
Asana, Inc. (ASAN) I see a move to $39.*** Chart read.
$33.81+1.89 (+5.91%)
As of 3:54PM EST.
Asana, Inc. (ASAN) I see a move to $39.*** Chart read.
$33.81+1.89 (+5.91%)
As of 3:54PM EST.
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
- 5 hours ago
All proposals at special meeting passed. Merger is a go.
-
8 hours ago
Today is the merger day from $IPV and $AEVA.IPV that will go to AEVA today. Its not only in autonoumes car driving, where they are with Audi, Porsche etc. also they have a huge potential in Industrial Robots, Smartphones / Tablets and a lot more
janes-- from Skillz- I found that what happens is initially these web sites will not have the new symbol and you will still have to click to the old symbol then after a few weeks they have the new symbol and that gets grouped on the side when Yahoo does it's competitors or other people are watching... and then you can get ready to make some money. The 1st initiations from analysts as the new company ought to be very helpful as well... Hopefully they have saved a large contract (I would) and drop that next week! ~si
I give. I give. I give.
Vicor Corporation (VICR) stocks that hit $100 Club!
$99.90+5.18 (+5.47%)
At close: 4:00PM EST
Vicor Corporation (VICR) stocks that hit $100 Club!
$99.90+5.18 (+5.47%)
At close: 4:00PM EST
i bought a couple more. just a few.
Great News For Women! Investing with GBA means saving people. Co given ok to dose patient!
Must get 1 more Ok then a life could be saved...
Atossa receives FDA 'Safe to Proceed' letter for ovarian cancer treatment 09:33 ATOS Atossa Therapeutics announced the FDA has issued a "Safe to Proceed" letter under their Expanded Access Pathway, permitting the use of Atossa's oral Endoxifen as a treatment in an ovarian cancer patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief. Under the FDA expanded access program, the use of Atossa's proprietary oral Endoxifen is restricted solely to this patient. Approval from the Institutional Review Board must be obtained prior to providing oral Endoxifen to this patient.
ATOS $ 3.23 up 11% ! Me Thinks This Is Going To Explode Up!
Must get 1 more Ok then a life could be saved...
Atossa receives FDA 'Safe to Proceed' letter for ovarian cancer treatment 09:33 ATOS Atossa Therapeutics announced the FDA has issued a "Safe to Proceed" letter under their Expanded Access Pathway, permitting the use of Atossa's oral Endoxifen as a treatment in an ovarian cancer patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief. Under the FDA expanded access program, the use of Atossa's proprietary oral Endoxifen is restricted solely to this patient. Approval from the Institutional Review Board must be obtained prior to providing oral Endoxifen to this patient.
ATOS $ 3.23 up 11% ! Me Thinks This Is Going To Explode Up!
Van RRR How did I do?
-Top Tick
-Top Tick
TIME TO BUY DROPBOX.
Dropbox director buys 100K shares of common stock 18:54 DBX In a regulatory filing, Dropbox disclosed that its board member Bob Mylod bought 100K shares of common stock on March 10th in a transaction totaling $2.46M, boosting his stake by 50%.
Dropbox director buys 100K shares of common stock 18:54 DBX In a regulatory filing, Dropbox disclosed that its board member Bob Mylod bought 100K shares of common stock on March 10th in a transaction totaling $2.46M, boosting his stake by 50%.
NormaLLy this would be bad news-
Spero Therapeutics files $300M mixed securities shelf 17:01 SPRO
These days? Often good...
Spero Therapeutics files $300M mixed securities shelf 17:01 SPRO
These days? Often good...
Pot stocks corrected some like Grow Gen quite a bit! Relative strength stand out-
A) TCNNF
Trulieve Cannabis(OTCQX:TCNNF)lower 2.3% over the past week.
B) CURL
Curaleaf(OTCPK:CURLF) declined 12% in two weeks,@ $49.36
These are the two we picked out last thread MUCH lower.......
A) TCNNF
Trulieve Cannabis(OTCQX:TCNNF)lower 2.3% over the past week.
B) CURL
Curaleaf(OTCPK:CURLF) declined 12% in two weeks,@ $49.36
These are the two we picked out last thread MUCH lower.......